Evidence map›Paper›PMID 32983113›Full record

ArticleFrontiers in immunology2020

The Production of Pro-angiogenic VEGF-A Isoforms by Hypoxic Human NK Cells Is Independent of Their TGF-β-Mediated Conversion to an ILC1-Like Phenotype.

Lindsey G Hawke, Mara K M Whitford, Mark L Ormiston

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Butyrate enhances CD56Genes and immunity · 2025
    Article
  6. Article
  7. Investigation of the Neurotoxicity Mechanisms of NiInternational journal of molecular sciences · 2025
    Article
  8. Review
  9. Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization.Journal of immunology (Baltimore, Md. : 1950) · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Plasticity of NK cells in Cancer.Frontiers in immunology · 2022
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lindsey G HawkeDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Mara K M WhitfordDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Mark L OrmistonDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Queen's University · CA

Funding

CIHR PJT-152916
6 · The paper itself

Abstract

Circulating natural killer (NK) cells have been shown to adopt a type 1 innate lymphoid cell (ILC1)-like phenotype in response to TGF-β and secrete VEGF-A when exposed to hypoxia. Although these changes are often considered to be linked attributes of tissue residency, it has yet to be determined if TGF-β and hypoxia work in concert to coordinate NK cellular phenotype and angiogenic potential. Examination of human circulating NK cells treated with TGF-β demonstrated heterogeneity in their potential to adopt an ILC1-like phenotype, as indicated by the upregulation of CD9 and CD103 on only a subset of cells in culture. Culturing NK cells in chronic hypoxia did not induce a similar ILC1-like conversion and did not enhance the degree of conversion for cells exposed to TGF-β. Similarly, hypoxic culture of circulating NK cells induced VEGF-A secretion, but this production was not enhanced by TGF-β. Fluorescent

Indexed as

Cell HypoxiaCells, CulturedHumansKiller Cells, NaturalPhenotypeProtein IsoformsTime FactorsTransforming Growth Factor betaUp-RegulationVascular Endothelial Growth Factor AProtein IsoformsTransforming Growth Factor betaVascular Endothelial Growth Factor AVEGFA protein, humanangiogenesisnatural killer cellstissue residencytransforming growth factor-βvascular endothelial growth factor-A

Identifiers

PMID32983113
PMCPMC7477355
OpenAlexW3080140552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.